Former Cordis chairman joins board of stent start-up
This article was originally published in Clinica
Privately-held stent developer Svelte Medical Systems has elected Robert Croce, a former worldwide franchise chairman of Johnson & Johnson-subsidiary Cordis, to its board of directors. Mr Croce spent 36 years at Johnson & Johnson, 12 of these as company group chairman. The appointment comes after Svelte completed an extension to its series A financing. The New Providence, New Jersey firm first announced it had raised the additional $6m in December, bringing the total investment in the company to $20m (www.clinica.co.uk, 9 December 2009). Investors in the firm include CNF Investments, Apjohn Ventures, the Fischell family and Norwich Ventures. Founded in 2007, Svelte is developing its Stent-on-a-Wire system, which is described as "a low-profile, highly flexible stent system which navigates the vasculature in a similar fashion to a traditional guidewire". The company initiated European clinical trials of the device in January and is looking to CE mark the product in the middle of this year, with a drug-eluting version to follow in 2011 (www.clinica.co.uk, 11 January 2010).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.